The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).
Robert Collins
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose
Mark J. Levis
No relevant relationships to disclose
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Arog (U); Astellas Pharma (U)
Abhijit Ramachandran
Employment or Leadership Position - Arog
Farhad Ravandi
No relevant relationships to disclose
Nora Ku
Employment or Leadership Position - Arog
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Astellas Pharma; Novartis
Research Funding - Ambit BioSciences; ARIAD; Arog; Astellas Pharma; Cell Therapeutics; Novartis